Jennifer C. Hoblyn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jennifer C. Hoblyn has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
Terence A. Ketter
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA
6 shared publications- John O. Brooks
JOHN O BROOKS III PhD MD, Assistant Professor of Psychiatry, School of Medicine, Stanford University, Stanford, CA; Director of Inpatient Psychiatry, Palo Alto Veterans Affairs Health Care System, Palo Alto, CA
5 shared publications Allyson C. Rosen
Palo Alto Veterans Affairs Health Care System, Palo Alto
4 shared publications- Jerome A. Yesavage
Department of Veterans Affairs Health Care System, Palo Alto, CA, USA
4 shared publications John O. Brooks
UCLA Semel Institute, Los Angeles, CA, United States
4 shared publicationsJulie C. Bonner
4 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Qualitative insights from partners of individuals with Huntington’s disease: the quality of life of an under-researched population
Objective: Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder with profound psychosocial consequences extending beyond affected individuals to their families. This qualitative study explored the quality of life (QoL) of partners of individuals with HD, manifest (mHD) and premanifest (preHD), using a needs-based theoretical framework. Background: While the impact of HD on patients is well documented, the experiences of partners remain under-researched, particularly across different stages of disease progression. Understanding partner QoL is essential to inform holistic care in rare neurodegenerative diseases. Methods: Semi-structured interviews were conducted with adult partners or spouses of mHD or preHD individuals in the UK and Ireland ( n = 60; UK = 48, Ireland = 12). An additional 37 interviews were conducted across Europe to assess cross-cultural consistency. Data were analysed using thematic analysis informed by the needs-based model of QoL. Results: Thematic analysis identified 376 statements from partners of mHD individuals and 491 from partners of preHD individuals. For partners of mHD individuals, key themes discussed included strained relationships, reduced communication, and loss of shared activities. Partners of preHD individuals reported preoccupation with worry, relationship difficulties, and uncertainty about the future. Findings were consistent across participating European countries, highlighting the widespread and cross-cultural nature of these challenges. Conclusion: HD significantly constrains partners’ ability to fulfil key human needs, negatively affecting QoL across disease stages. This study provides novel, theory-driven insights into an under-recognised population in rare disease research and supports the development of partner-specific QoL measures. These findings have important implications for the design and evaluation of interventions aimed at improving outcomes for families affected by HD and other rare neurodegenerative conditions.
- 10 November 2026
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 21 (1)
Open AccessQualitative insights from partners of individuals with Huntington’s disease: the quality of life of an under-researched population
Objective: Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder with profound psychosocial consequences extending beyond affected individuals to their families. This qualitative study explored the quality of life (QoL) of partners of individuals with HD, manifest (mHD) and premanifest (preHD), using a needs-based theoretical framework. Background: While the impact of HD on patients is well documented, the experiences of partners remain under-researched, particularly across different stages of disease progression. Understanding partner QoL is essential to inform holistic care in rare neurodegenerative diseases. Methods: Semi-structured interviews were conducted with adult partners or spouses of mHD or preHD individuals in the UK and Ireland ( n = 60; UK = 48, Ireland = 12). An additional 37 interviews were conducted across Europe to assess cross-cultural consistency. Data were analysed using thematic analysis informed by the needs-based model of QoL. Results: Thematic analysis identified 376 statements from partners of mHD individuals and 491 from partners of preHD individuals. For partners of mHD individuals, key themes discussed included strained relationships, reduced communication, and loss of shared activities. Partners of preHD individuals reported preoccupation with worry, relationship difficulties, and uncertainty about the future. Findings were consistent across participating European countries, highlighting the widespread and cross-cultural nature of these challenges. Conclusion: HD significantly constrains partners’ ability to fulfil key human needs, negatively affecting QoL across disease stages. This study provides novel, theory-driven insights into an under-recognised population in rare disease research and supports the development of partner-specific QoL measures. These findings have important implications for the design and evaluation of interventions aimed at improving outcomes for families affected by HD and other rare neurodegenerative conditions.
- Open Access
- 11 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7)
Development and validation of the first needs-based quality of life measure for individuals with manifest Huntington’s disease
Background: Huntington’s disease (HD) is a progressive, hereditary neurodegenerative disorder currently without curative treatments, thus making quality of life (QoL) an important outcome for clinical care and therapeutic evaluation. Existing HD-specific patient-reported outcome measures (PROMs) do not adequately capture the experiences of individuals with manifest HD. This study presents the multinational development and validation of the Huntington’s Disease Manifest Quality of Life measure (HD-mQoL), the first needs-based, disease-specific PROM for assessing QoL in individuals with manifest HD. Methods: Development followed three stages: (1) generation of measure content and translations; (2) testing of face and content validity; and (3) psychometric validation using data from a large international survey analysed with Rasch Measurement Theory (RMT) and Classical Test Theory (CTT). Results: The measure was completed by 238 individuals with manifest HD from the Czech Republic, Germany, Ireland, Italy, and the UK (59% male; age range 20–83 years). Rasch analysis reduced 49 items to a final set of 23, demonstrating good model fit (item–trait interaction χ 2 = 0.391), unidimensionality, no differential item functioning, no local dependency, and excellent reliability (Cronbach’s α = 0.91 at timepoint 1, 0.92 at timepoint 2; test–retest r = 0.87). The final measure showed minimal floor and ceiling effects and correlated moderately to strongly with relevant Nottingham Health Profile domains. HD-mQoL scores effectively differentiated subgroups by self-rated disease severity and general health (p < 0.001). Conclusions: The HD-mQoL is a robust, needs-based measure of QoL, suitable for international use in clinical practice and trials assessing treatment value from the patient’s perspective.
- 11 June 2026
- Published by Springer Nature in Journal of Neurology
- Vol. 273 (7)
Open AccessDevelopment and validation of the first needs-based quality of life measure for individuals with manifest Huntington’s disease
Background: Huntington’s disease (HD) is a progressive, hereditary neurodegenerative disorder currently without curative treatments, thus making quality of life (QoL) an important outcome for clinical care and therapeutic evaluation. Existing HD-specific patient-reported outcome measures (PROMs) do not adequately capture the experiences of individuals with manifest HD. This study presents the multinational development and validation of the Huntington’s Disease Manifest Quality of Life measure (HD-mQoL), the first needs-based, disease-specific PROM for assessing QoL in individuals with manifest HD. Methods: Development followed three stages: (1) generation of measure content and translations; (2) testing of face and content validity; and (3) psychometric validation using data from a large international survey analysed with Rasch Measurement Theory (RMT) and Classical Test Theory (CTT). Results: The measure was completed by 238 individuals with manifest HD from the Czech Republic, Germany, Ireland, Italy, and the UK (59% male; age range 20–83 years). Rasch analysis reduced 49 items to a final set of 23, demonstrating good model fit (item–trait interaction χ 2 = 0.391), unidimensionality, no differential item functioning, no local dependency, and excellent reliability (Cronbach’s α = 0.91 at timepoint 1, 0.92 at timepoint 2; test–retest r = 0.87). The final measure showed minimal floor and ceiling effects and correlated moderately to strongly with relevant Nottingham Health Profile domains. HD-mQoL scores effectively differentiated subgroups by self-rated disease severity and general health (p < 0.001). Conclusions: The HD-mQoL is a robust, needs-based measure of QoL, suitable for international use in clinical practice and trials assessing treatment value from the patient’s perspective.
- 1 January 2013
- Published by Wolters Kluwer Health in Journal of Head Trauma Rehabilitation
- Vol. 28 (1) , 39-47
Predictors of Inpatient and Outpatient Healthcare Utilization in Veterans With Traumatic Brain Injury
Objective: Traumatic brain injury (TBI) can place a significant financial and resource burden on healthcare systems. This study examined predictors of outpatient and inpatient healthcare utilization in veterans with a history of TBI. Methods: A secondary analysis was conducted on data from 1565 veterans with TBI and 1565 veterans without TBI seen for healthcare services at the VA Palo Alto Health Care System between 2000 and 2010. Patterns and predictors of outpatient and inpatient medical and psychiatric care were examined. Results: Veterans with TBI utilized significantly more services compared with the control group. The TBI group was seen for more than 160 000 outpatient services and was almost 9 times more likely to be hospitalized than the control group. Although psychiatric disorders were more prevalent in the TBI group and associated with increased medical and mental health utilization within the TBI group, they did not account fully for the significant group differences. Conclusions: Veterans with a history of TBI have much greater healthcare needs than veterans without TBI, likely because of non–TBI-related factors. Increased monitoring and early intervention treatments may be warranted for certain at-risk veterans with the goal of minimizing their need for long-term or extensive healthcare services in the future.
- 1 January 2013
- Published by Wolters Kluwer Health in Journal of Head Trauma Rehabilitation
- Vol. 28 (1) , 39-47
Predictors of Inpatient and Outpatient Healthcare Utilization in Veterans With Traumatic Brain Injury
Objective: Traumatic brain injury (TBI) can place a significant financial and resource burden on healthcare systems. This study examined predictors of outpatient and inpatient healthcare utilization in veterans with a history of TBI. Methods: A secondary analysis was conducted on data from 1565 veterans with TBI and 1565 veterans without TBI seen for healthcare services at the VA Palo Alto Health Care System between 2000 and 2010. Patterns and predictors of outpatient and inpatient medical and psychiatric care were examined. Results: Veterans with TBI utilized significantly more services compared with the control group. The TBI group was seen for more than 160 000 outpatient services and was almost 9 times more likely to be hospitalized than the control group. Although psychiatric disorders were more prevalent in the TBI group and associated with increased medical and mental health utilization within the TBI group, they did not account fully for the significant group differences. Conclusions: Veterans with a history of TBI have much greater healthcare needs than veterans without TBI, likely because of non–TBI-related factors. Increased monitoring and early intervention treatments may be warranted for certain at-risk veterans with the goal of minimizing their need for long-term or extensive healthcare services in the future.
- 11 November 2012
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 84 (2) , 209-218
Veteran Subjects Willingness to Participate in Schizophrenia Clinical Trials
Predictive characteristics of subjects agreeing to be randomized into clinical trials for the treatment of schizophrenia and schizoaffective disorder have been little studied. In this study, we used data from the recruitment phase of a randomized trial that compared long acting injectable (LAI) risperidone to oral antipsychotic medications. Basic socio-demographic and clinical data were gathered from eligible patients and clinicians at the time of screening for trial entry. Bivariate comparisons and multivariate logistic regression were used to compare those who agreed to participate and those who refused. Altogether 446 veterans were eligible on preliminary screening, of these 382 (86 %) agreed to participate and 64 (14 %) declined. Eligible patients who agreed to be randomized were more willing to change medications without regard to their level of satisfaction with their current medication. Subjects reported as currently taking LAI medication and taking risperidone, in particular, were more likely to agree to participate. Factors that did not significantly predict participation included age, years on current medication, reported medication compliance, race, and gender. Veterans with schizophrenia or schizoaffective disorder who were actually more satisfied with their current medications and who were currently taking the experimental agent were more likely to agree to participate in this randomized clinical trial in contrast to expectations that individuals who are unsatisfied with their current treatment would be more likely to enroll in such studies.
- 11 November 2012
- Published by Springer Nature in Psychiatric Quarterly
- Vol. 84 (2) , 209-218
Veteran Subjects Willingness to Participate in Schizophrenia Clinical Trials
Predictive characteristics of subjects agreeing to be randomized into clinical trials for the treatment of schizophrenia and schizoaffective disorder have been little studied. In this study, we used data from the recruitment phase of a randomized trial that compared long acting injectable (LAI) risperidone to oral antipsychotic medications. Basic socio-demographic and clinical data were gathered from eligible patients and clinicians at the time of screening for trial entry. Bivariate comparisons and multivariate logistic regression were used to compare those who agreed to participate and those who refused. Altogether 446 veterans were eligible on preliminary screening, of these 382 (86 %) agreed to participate and 64 (14 %) declined. Eligible patients who agreed to be randomized were more willing to change medications without regard to their level of satisfaction with their current medication. Subjects reported as currently taking LAI medication and taking risperidone, in particular, were more likely to agree to participate. Factors that did not significantly predict participation included age, years on current medication, reported medication compliance, race, and gender. Veterans with schizophrenia or schizoaffective disorder who were actually more satisfied with their current medications and who were currently taking the experimental agent were more likely to agree to participate in this randomized clinical trial in contrast to expectations that individuals who are unsatisfied with their current treatment would be more likely to enroll in such studies.
- 10 January 2012
- Published by Elsevier in Journal of Affective Disorders
- Vol. 137 (1-3) , 139-145
Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients
- 10 January 2012
- Published by Elsevier in Journal of Affective Disorders
- Vol. 137 (1-3) , 139-145
Effectiveness of quetiapine plus lamotrigine maintenance therapy in challenging bipolar disorder patients
- 22 December 2010
- Published by Wiley in Bipolar Disorders
- Vol. 12 (8) , 866-874
Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder
Brooks JO III, Bearden CE, Hoblyn JC, Woodard SA, Ketter TA. Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder. Bipolar Disord 2010: 12: 866–874. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.Objective: Reports of sustained attention deficits in the euthymic phase of bipolar disorder have been variable, and have yet to be related to cerebral metabolism. In the present study, we evaluated relationships between cognitive performance deficits and resting cerebral metabolism in euthymic older adults with bipolar disorder.Methods: Sixteen older (mean age 58.7 years) euthymic outpatients with bipolar disorder (10 type I, 6 type II; 44% female) and 11 age‐matched healthy controls received resting positron emission tomography with 18fluorodeoxyglucose and, within 10 days, the Conners’ Continuous Performance Test‐II, a commonly used measure of sustained attention and inhibitory control.Results: Bipolar disorder patients had significantly more omission errors (z = 2.53, p = 0.01) and a trend toward more commission errors (z = 1.83, p < 0.07) than healthy controls. Relative to healthy controls, among bipolar disorder subjects commission errors were more strongly related to inferior frontal gyrus [Brodmann area (BA) 45/47] hypometabolism and paralimbic hypermetabolism. In bipolar disorder subjects, relative to controls, omission errors were more strongly related to dorsolateral prefrontal (BA 9/10) hypometabolism and greater paralimbic, insula, and cingulate hypermetabolism.Conclusions: In older adults with bipolar disorder, even during euthymia, resting‐state corticolimbic dysregulation was related to sustained attention deficits and inhibitory control, which could reflect the cumulative impact of repeated affective episodes upon cerebral metabolism and neurocognitive performance. The relative contributions of aging and recurrent affective episodes to these differences in bipolar disorder patients remain to be established.
- 22 December 2010
- Published by Wiley in Bipolar Disorders
- Vol. 12 (8) , 866-874
Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder
Brooks JO III, Bearden CE, Hoblyn JC, Woodard SA, Ketter TA. Prefrontal and paralimbic metabolic dysregulation related to sustained attention in euthymic older adults with bipolar disorder. Bipolar Disord 2010: 12: 866–874. © 2010 The Authors. Journal compilation © 2010 John Wiley & Sons A/S.Objective: Reports of sustained attention deficits in the euthymic phase of bipolar disorder have been variable, and have yet to be related to cerebral metabolism. In the present study, we evaluated relationships between cognitive performance deficits and resting cerebral metabolism in euthymic older adults with bipolar disorder.Methods: Sixteen older (mean age 58.7 years) euthymic outpatients with bipolar disorder (10 type I, 6 type II; 44% female) and 11 age‐matched healthy controls received resting positron emission tomography with 18fluorodeoxyglucose and, within 10 days, the Conners’ Continuous Performance Test‐II, a commonly used measure of sustained attention and inhibitory control.Results: Bipolar disorder patients had significantly more omission errors (z = 2.53, p = 0.01) and a trend toward more commission errors (z = 1.83, p < 0.07) than healthy controls. Relative to healthy controls, among bipolar disorder subjects commission errors were more strongly related to inferior frontal gyrus [Brodmann area (BA) 45/47] hypometabolism and paralimbic hypermetabolism. In bipolar disorder subjects, relative to controls, omission errors were more strongly related to dorsolateral prefrontal (BA 9/10) hypometabolism and greater paralimbic, insula, and cingulate hypermetabolism.Conclusions: In older adults with bipolar disorder, even during euthymia, resting‐state corticolimbic dysregulation was related to sustained attention deficits and inhibitory control, which could reflect the cumulative impact of repeated affective episodes upon cerebral metabolism and neurocognitive performance. The relative contributions of aging and recurrent affective episodes to these differences in bipolar disorder patients remain to be established.
- 1 October 2010
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 44 (14) , 921-929
Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting
- 1 October 2010
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 44 (14) , 921-929
Long-term effectiveness of quetiapine in bipolar disorder in a clinical setting
- 1 February 2010
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 181 (2) , 136-140
Metabolic evidence of corticolimbic dysregulation in bipolar mania
- 1 February 2010
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 181 (2) , 136-140
Metabolic evidence of corticolimbic dysregulation in bipolar mania
- 1 December 2009
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 17 (12) , 1022-1029
Resting Prefrontal Hypometabolism and Paralimbic Hypermetabolism Related to Verbal Recall Deficits in Euthymic Older Adults With Bipolar Disorder
- 1 December 2009
- Published by Elsevier in The American Journal of Geriatric Psychiatry
- Vol. 17 (12) , 1022-1029
Resting Prefrontal Hypometabolism and Paralimbic Hypermetabolism Related to Verbal Recall Deficits in Euthymic Older Adults With Bipolar Disorder
- 1 June 2009
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 172 (3) , 200-204
Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression
- 1 June 2009
- Published by Elsevier in Psychiatry Research: Neuroimaging
- Vol. 172 (3) , 200-204
Dorsolateral and dorsomedial prefrontal gray matter density changes associated with bipolar depression